Cargando…

Secreted and tumour targeted human carboxylesterase for activation of irinotecan

Irinotecan (CPT-11) is an anticancer agent for the treatment of colon cancer. CPT-11 can be considered as a prodrug, since it needs to be activated into the toxic drug SN-38 by the enzyme carboxylesterase. An approach to achieve tumour specific activation of CPT-11 is to transduce the cDNA encoding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oosterhoff, D, Pinedo, H M, van der Meulen, I H, de Graaf, M, Sone, T, Kruyt, F A, van Beusechem, V W, Haisma, H J, Gerritsen, W R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364240/ https://www.ncbi.nlm.nih.gov/pubmed/12237777 http://dx.doi.org/10.1038/sj.bjc.6600519

Ejemplares similares

Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11
por: Oosterhoff, D, et al.
Publicado: (2005)

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug
por: de Graaf, M, et al.
Publicado: (2002)

Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity
por: de Bruin, M, et al.
Publicado: (2003)

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts
por: Geoerger, B, et al.
Publicado: (2003)

No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan
por: Calvet, L, et al.
Publicado: (2004)

Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL
por: Abou El Hassan, M A I, et al.
Publicado: (2004)

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma
por: Granda, T G, et al.
Publicado: (2002)

Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth
por: Wang, M-H, et al.
Publicado: (2004)

Consumption of an omega-3 fatty acids product, INCELL AAFA™, reduced side-effects of CPT-11 (irinotecan) in mice
por: Hardman, W E, et al.
Publicado: (2002)

Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines
por: Bergman, A M, et al.
Publicado: (2003)

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy
por: Teft, W A, et al.
Publicado: (2015)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Invasion and MMP expression profile in desmoid tumours
por: Denys, H, et al.
Publicado: (2004)

Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity
por: Seynhaeve, A L B, et al.
Publicado: (2002)

Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006)

Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth
por: Park, I-S, et al.
Publicado: (2003)

Effects of Dantrolene Therapy on Disease Phenotype in Dystrophin Deficient mdx Mice
por: Quinn, James L, et al.
Publicado: (2013)

Ischaemia-reperfusion injury in photodynamic therapy-treated mouse tumours
por: Korbelik, M, et al.
Publicado: (2003)

Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity
por: van Hattum, A H, et al.
Publicado: (2002)

Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
por: Rudek, Michelle A., et al.
Publicado: (2016)

Selectivity of the photosensitiser Tookad® for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tumour model
por: Borle, F, et al.
Publicado: (2003)

Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma
por: Budach, W, et al.
Publicado: (2002)

Melanoma cell migration is upregulated by tumour necrosis factor-α and suppressed by α-melanocyte-stimulating hormone
por: Zhu, N, et al.
Publicado: (2004)

Uptake and localisation of mTHPC (Foscan®) and its(14)C-labelled form in normal and tumour tissues of the hamster squamous cell carcinoma model: a comparative study
por: Blant, S Andrejevic, et al.
Publicado: (2002)

Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin
por: Sersa, G, et al.
Publicado: (2002)

In vivo evolution of tumour cells after the generation of double-strand DNA breaks
por: Mekid, H, et al.
Publicado: (2003)

Changes in the ornithine cycle following ionising radiation cause a cytotoxic conditioning of the culture medium of H35 hepatoma cells
por: van Rijn, J, et al.
Publicado: (2003)

Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells
por: Scheffer, G L, et al.
Publicado: (2002)

Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan® localisation in cultured tumour cells
por: Teiten, M-H, et al.
Publicado: (2003)

A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors
por: Shimamura, M, et al.
Publicado: (2003)

A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer
por: Houba, P H J, et al.
Publicado: (2001)

Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia
por: Thews, O, et al.
Publicado: (2004)

Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL
por: Rikhof, B, et al.
Publicado: (2008)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

ALA and ALA hexyl ester in free and liposomal formulations for the photosensitisation of tumour organ cultures
por: Casas, A, et al.
Publicado: (2002)

Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment
por: Lee, W-N P, et al.
Publicado: (2004)

Non-invasive (19)F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours
por: Dresselaers, T, et al.
Publicado: (2003)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung
por: Ono, K, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_gso52omr7qcpccjjri0ijtmrbh